InSilicoMinds provides AI‑driven modeling and simulation services for pharmaceutical and life‑science companies, enabling faster, lower‑cost drug development and regulatory submissions. By leveraging validated computational tools and an exclusive partnership with InSilicoTrials, they create digital twins and biosimulations that can cut development timelines by up to 50% and improve patient outcomes. Their offerings span generic drug formulation, vaccine design, and drug discovery consulting.
Funding
Funding not disclosed
Founders
Product
Problem
Pharmaceutical and life‑science companies face lengthy, costly drug development cycles, with high failure rates and extensive regulatory requirements that delay market entry and increase R&D expenses.
Solution
InSilicoMinds provides AI‑enhanced modeling and simulation services that create digital twins of drugs, formulations, and clinical trials. By integrating best‑in‑class validated software with proprietary in‑house tools, the platform enables biosimulations for generics, APIs, vaccines, and new molecular entities. These simulations predict pharmacokinetics, safety, efficacy, and manufacturing outcomes, allowing companies to de‑risk candidates early and shorten development timelines by up to 50%. The service also supports regulatory submissions with Good Simulation Practice (GSP) compliant documentation, facilitating acceptance of in‑silico evidence by agencies such as the FDA. Clients receive actionable insights through expert consultancy, staff augmentation, and customized computational workflows.
Target Audience
Primary customers are pharmaceutical manufacturers, biotech firms, and contract research organizations seeking to accelerate drug discovery, development, and regulatory approval for new drugs, generics, and vaccines.
Features
- AI‑driven pharmacokinetic/pharmacodynamic (PK/PD) and physiologically based pharmacokinetic (PBPK) modeling for rapid candidate assessment
- Digital twin and biosimulation of drug products, including solid oral, injectables, transdermal patches, and APIs
- End‑to‑end virtual clinical trial simulations to support efficacy, safety, and bioequivalence studies
- Integration of validated global modeling tools with proprietary algorithms under Good Simulation Practice (GSP) standards
- Regulatory‑ready deliverables and documentation to support in‑silico evidence in dossier submissions
- Domain advisory and consultancy services, plus staff augmentation for project‑specific expertise